4B0G

Complex of Aurora-A bound to an Imidazopyridine-based inhibitor

Summary for 4B0G

• Entry DOI: 10.2210/pdb4b0g/pdb
• Related: 1MQ4 1MUO 1OL5 1OL6 1OL7 2BMC 2C6D 2C6E 2J4Z 2J50 2W1C 2W1D 2W1E 2W1F 2W1G 2WQE 2WTV 2WTW 2X6D 2X6E 2X81 2XNE 2XNG 2XRU
• Descriptor: AURORA KINASE A, 6-bromo-2-(1-methyl-1H-imidazol-5-yl)-7-{4-[(5-methyl-1,2-oxazol-3-yl)methyl]piperazin-1-yl}-1H-imidazo[4,5-b]pyridine, SULFATE ION, ... (4 entities in total)
• Functional Keywords: transferase, mitosis
• Biological source: HOMO SAPIENS (HUMAN)
• Cellular location: Cytoplasm, cytoskeleton, centrosome: O14965
• Total number of polymer chains: 1
• Total formula weight: 33662.24

Authors

Kosmopoulou, M.,Bayliss, R. (deposition date: 2012-07-02, release date: 2013-03-13, Last modification date: 2023-12-20)

• Primary citation: Bavetsias, V.,Crumpler, S.,Sun, C.,Avery, S.,Atrash, B.,Faisal, A.,Moore, A.S.,Kosmopoulou, M.,Brown, N.,Sheldrake, P.W.,Bush, K.,Henley, A.,Box, G.,Valenti, M.,De Haven Brandon, A.,Raynaud, F.I.,Workman, P.,Eccles, S.A.,Bayliss, R.,Linardopoulos, S.,Blagg, J.; Optimization of Imidazo[4,5-B]Pyridine-Based Kinase Inhibitors: Identification of a Dual Flt3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia.; J.Med.Chem., 55:8721-, 2012; PubMed: 23043539; DOI: 10.1021/JM300952S

Experimental method

X-RAY DIFFRACTION (2.5 Å)